| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.031 | 0.8 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.8 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |